Nashville Oncology Associates is excited to announce our status as a study location in the Phase 1/2 clinical trial, CHAMP-1. The trial is an open-label, multi-center study for patients with advanced solid tumors or diffuse large B-cell lymphoma (DLBCL).
The Phase 1/2 clinical trial CHAMP-1, sponsored by Ranok Therapeutics Co. Ltd, studies the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of the novel treatment, RNK05047. RNK05047 uses Ranok Therapeutics’ CHAMP™ technology for targeted protein degradation. It is the first therapy of its kind to enter clinical testing.
The investigational new drug application for RNK05047 was cleared by the U.S. Food and Drug Administration (FDA) in January 2022. Patient dosing for this study was initiated in August of the same year.
We are proud to bring this open-label, multi-center trial to Middle Tennessee. Offering novel therapies in a community setting through early-stage clinical trials requires an unyielding commitment to safety, accuracy, and precision in data and trial administration. By being integrally involved in clinical research in this way, we continue our commitment to providing more treatment options and better care for our patients.
For More Information:
Currently enrolled patients at our location began the trial last week. The study is open and still actively enrolling. You can find more information on this trial and view other actively enrolling clinical trials in the Verdi Oncology network at https://VerdiClinicalResearch.com/list-of-trials.
The National Clinical Trial number at ClinicalTrials.gov is NCT05487170.